



February 8, 2019

Via E-mail: AGO.highcostprescriptiondrugs@vermont.gov

Re: Notice of New Drug Introduction Pursuant to 18 V.S.A. s. 4637

To Whom It May Concern:

Teva Pharmaceuticals USA, Inc. (“Teva”) submits this information pursuant to 18 V.S.A. s. 4637(b). On February 6, 2019, Teva released the following generic prescription drug to the commercial market:

NDC	Product Description	WAC
00591-3851-01	VIGABATRIN 500MG TABLETS 100	\$11,487.30

Teva reserves any and all rights that it may have to challenge the governing statute, its interpretation, or its application to Teva.

Thank you for your consideration.

Sincerely,

Brian Savage
General Counsel, US Generics
Teva Pharmaceuticals USA, Inc.